100+
pipeline drugs in the Diffuse Large B Cell Lymphoma pipeline landscape. It comprises DLBCL pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Diffuse Large B Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights the inactive DLBCL pipeline products.
Some of the significant
Highlights Several prominent companies such as ADC Therapeutics, BeiGene, Nordic Nanovector, bluebird bio, Celgene, GlaxoSmithKline, AbbVie, Roche and many others are working to assess challenges and seek opportunities that could influence Diffuse Large B-cell Lymphoma R&D. The DLBCL pipeline therapies are focused on novel approaches for the treatment.
Esbriet, and Ofev (tyrosine kinase inhibitors). Both drugs have been shown to slow the disease progression but do not significantly impact mortality.
The surge in Idiopathic Pulmonary Fibrosis market size is due to an increase in the prevalence of IPF patients in the 7MM, along with promising assets such as
RG 6354, Pamrevlumab,
Of all the emerging therapies, the most anticipated product to launch is the
RG 6354 (Roche). It has received Breakthrough Therapy Designation from the FDA. Apart from this, other products such as
Pamrevlumab,
, Ziritaxestat, GB0139, and others have demonstrated early promising results.
The IPF market will experience a boost in market growth owing to the factors such as the market entry of novel therapies aided by the grant given by the special regulatory designations, an increase in the aging population, and an increase in the prevalence of fibrotic diseases in those population. However, the poor prognosis of IPF patients, lack of curative